Matching trials
1,853 results
- CORONAIndependent statistical analysis of the randomized phase 3 CORONA trial of levilimab versus placebo in patients with severe COVID-19, including the primary endpoint, trial design, planned statistical analysis, and interpretation.
- COU-AA-301Independent statistical analysis of COU-AA-301, a randomized phase 3 trial of abiraterone acetate in castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy, covering overall survival, progression, PSA response, trial design, and statistical…
- COV-BARRIERComplete statistical analysis of the COV-BARRIER phase 3 trial of baricitinib plus standard of care versus placebo plus standard of care in participants with COVID-19, including trial design, endpoints, statistical methodology, reported…
- COV002Independent statistical analysis of COV002 (NCT04400838), a randomized phase 2/3 trial investigating ChAdOx1 nCoV-19 for prevention of COVID-19 in adults, including its design, endpoints, planned statistical methods, and interpretation.
- COV003Independent statistical analysis and educational interpretation of COV003, a phase 3 randomized study of ChAdOx1 nCoV-19 for prevention of COVID-19 disease confirmed with PCR.
- COVACTAIndependent statistical analysis of the randomized phase 3 COVACTA trial evaluating tocilizumab versus placebo in patients with severe COVID-19 pneumonia, including endpoint definitions, reported treatment effects, confidence intervals, p-values, and statistical methodology.
- COVACTAIndependent statistical analysis of A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- COVENANTIndependent statistical analysis of HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- COVID-19Complete statistical analysis of the randomized phase 3 COLCORONA trial of colchicine versus placebo in ambulatory patients with Corona Virus Infection, including trial design, endpoints, statistical methods, reported results, safety, and interpretation.
- COVID-19Independent statistical analysis of Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05973006).
- COVID-19 PEPComplete statistical analysis of the randomized phase 3 COVID-19 PEP trial of hydroxychloroquine versus placebo for post-exposure prophylaxis and preemptive therapy for SARS-CoV-2.
- COViNOXIndependent statistical analysis of A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- CoVPN 3006A detailed statistical analysis of CoVPN 3006, a randomized phase 3 crossover study evaluating Moderna COVID-19 Vaccine against SARS-CoV-2 infection and COVID-19 disease through the Month 4 study visit.
- CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus: Complete Statistical AnalysisIndependent statistical analysis of CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- CREDO 2Complete statistical analysis of the phase 3 CREDO 2 trial evaluating two olokizumab dosing regimens versus placebo and adalimumab in patients with active rheumatoid arthritis receiving methotrexate.
- CREDO 2Independent statistical analysis of Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate…
- CRISTALLOIndependent statistical analysis of A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT…
- Cross-vaccination Study of GSK Biologicals’ Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.: Complete Statistical AnalysisIndependent statistical analysis of Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.: primary endpoint results,…
- Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD: Complete Statistical AnalysisIndependent statistical analysis of Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD: primary endpoint results, effect estimate with…
- CROWN CORONAIndependent statistical analysis of the randomized phase 3 CROWN CORONA trial evaluating M-M-R II vaccine versus placebo for prevention of symptomatic COVID-19, including Bayesian logistic regression, risk differences, confidence intervals, p-values, and…
- CROWN CORONAIndependent statistical analysis of CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04333732).
- CTREPHIndependent statistical analysis of Efficacy and Tolerability of Subcutaneously Administered Treprostinil Sodium in Patients With Severe (Non-operable) Chronic Thromboembolic Pulmonary Hypertension (CTREPH): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- CURBIndependent statistical analysis of Cocaine Use Reduction With Buprenorphine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01402492).
- D Mannose in Recurrent Urinary Tract Infections: Complete Statistical AnalysisIndependent statistical analysis of D Mannose in Recurrent Urinary Tract Infections: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01808755).
- D-LUCSIndependent statistical analysis of Combined Pharmacotherapy for Cannabis Dependency: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01020019).
- DAHHS-2Independent statistical analysis of Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV: Complete Statistical AnalysisIndependent statistical analysis of Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- dal-GenEComplete statistical analysis of the phase 3 dal-GenE trial evaluating dalcetrapib versus placebo in a genetically defined population with a recent acute coronary syndrome, including trial design, time-to-event endpoints, Cox modeling, multiplicity,…
- dal-GenEIndependent statistical analysis of Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- DASISIONIndependent statistical analysis of the DASISION phase 3 trial of dasatinib versus imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia, including trial design, complete cytogenetic response, time-to-event analyses, statistical methodology,…
- DATAAn educational statistical analysis of the DATA phase 3 trial comparing 6 years with 3 years of adjuvant anastrozole after 2 to 3 years of tamoxifen in postmenopausal hormone-sensitive breast cancer.
- DAYBREAK-ALZIndependent statistical analysis of A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- DB2113361Independent statistical analysis of the randomized phase 3 DB2113361 trial evaluating UMEC/VI 125/25 µg and its components in chronic obstructive pulmonary disease, with emphasis on repeated-measures analysis of trough FEV1.
- DB2113373Complete statistical analysis of the phase 3 DB2113373 trial of UMEC/VI 62.5/25 µg, its components, and placebo in chronic obstructive pulmonary disease, including trial design, FEV1 methodology, mixed-effects modeling, reported estimates, confidence…
- DEFINEIndependent statistical analysis of DEFINE (NCT00420212), a phase 3 randomized, double-blind trial of oral BG00012 in relapsing-remitting multiple sclerosis, focusing on its 2-year time-to-event endpoint and statistical methodology.
- Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy: Complete Statistical AnalysisIndependent statistical analysis of Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01358760).
- DELIVERIndependent statistical analysis of the DELIVER phase 3 trial of dapagliflozin in heart failure with preserved ejection fraction, including its dual primary time-to-event endpoints, Cox models, recurrent-event analysis, KCCQ analysis, safety, and…
- DELIVERIndependent statistical analysis of Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- DEPICT 1Independent statistical analysis of Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02268214).
- DESTINATIONIndependent statistical analysis of the DESTINATION phase 3 trial of tezepelumab in adults and adolescents with severe, uncontrolled asthma, including trial design, registered endpoints, annualized asthma exacerbation rate results, safety, and statistical…
- DESTINATIONIndependent statistical analysis of Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- DESTINY-Breast04Independent statistical analysis of DESTINY-Breast04, a randomized phase 3 trial of trastuzumab deruxtecan versus investigator's choice for HER2-low breast cancer. Includes the reported progression-free survival analysis, trial design, statistical methodology, interpretation, and…
- DESTINY-Breast06Independent statistical analysis of DESTINY-Breast06 (NCT04494425), a randomized phase 3 trial comparing trastuzumab deruxtecan with investigator's choice chemotherapy in HER2-low, hormone receptor-positive, advanced or metastatic breast cancer.
- DESTINY-Breast09Independent statistical analysis of DESTINY-Breast09, the phase 3 randomized trial of trastuzumab deruxtecan with or without pertuzumab versus taxane, trastuzumab and pertuzumab in HER2-positive metastatic breast cancer.
- DESTINY-Gastric04An educational statistical analysis of DESTINY-Gastric04, a randomized phase 3 trial comparing trastuzumab deruxtecan with ramucirumab plus paclitaxel in HER2-positive gastric cancer or gastroesophageal junction adenocarcinoma after progression on or after a…
- DEVOTEIndependent statistical analysis of DEVOTE (NCT01959529), the double-blind cardiovascular outcomes trial of insulin degludec versus insulin glargine in 7637 people with type 2 diabetes, covering the Cox non-inferiority analysis of MACE, negative…
- DEVOTEIndependent statistical analysis of A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events: primary endpoint results, effect estimate…
- DexMabIndependent statistical analysis of Dextromethorphan as a Novel Non-opioid Adjunctive Agent for Pain Control in Medication Abortion: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- DFCI 10-106Independent statistical analysis of Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Diagnosis of Acute Appendicitis: Low-dose Computed Tomography (CT) Versus Standard-dose CT: Complete Statistical AnalysisIndependent statistical analysis of Diagnosis of Acute Appendicitis: Low-dose Computed Tomography (CT) Versus Standard-dose CT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…